Randomized Trial of Spheroid Reservoir Bioartificial Liver in Porcine Model of Posthepatectomy Liver Failure

被引:56
|
作者
Chen, Harvey S. [1 ]
Joo, Dong Jin [1 ,2 ]
Shaheen, Mohammed [1 ]
Li, Yi [1 ,3 ]
Wang, Yujia [1 ,3 ]
Yang, Jian [1 ,3 ]
Nicolas, Clara T. [1 ]
Predmore, Kelly [1 ]
Amiot, Bruce [1 ]
Michalak, Gregory [4 ]
Mounajjed, Taofic [5 ]
Fidler, Jeff [4 ]
Kremers, Walter K. [1 ,6 ]
Nyberg, Scott L. [1 ]
机构
[1] Mayo Clin, William J von Liebig Ctr Transplantat & Clin Rege, 200 First St, Rochester, MN 55905 USA
[2] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea
[3] Sichuan Univ, West China Hosp, Chengdu, Sichuan, Peoples R China
[4] Mayo Clin, Dept Radiol, Rochester, MN USA
[5] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[6] Mayo Clin, Dept Biostat, Rochester, MN USA
关键词
PORTAL-VEIN LIGATION; ALBUMIN DIALYSIS; HEPATIC-FAILURE; RESECTION; DEVICE; PIGS; HEPATECTOMY; EXCHANGE;
D O I
10.1002/hep.30184
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Acute liver failure (ALF) is a catastrophic condition that can occur after major liver resection. The aim of this study was to determine the effects of the spheroid reservoir bio-artificial liver (SRBAL) on survival, serum chemistry, and liver regeneration in posthepatectomy ALF pigs. Wild-type large white swine (20 kg-30 kg) underwent intracranial pressure (ICP) probe placement followed by 85% hepatectomy. Computed tomography (CT) volumetrics were performed to measure the extent of resection, and at 48 hours following hepatectomy to assess regeneration of the remnant liver. Animals were randomized into three groups based on treatment delivered 24-48 hours after hepatectomy: Group1-standard medical therapy (SMT, n = 6); Group2-SMT plus bio-artificial liver treatment using no hepatocytes (0 g, n = 6); and Group3-SMT plus SRBAL treatment using 200 g of primary porcine hepatocyte spheroids (200 g, n = 6). The primary endpoint was survival to 90 hours following hepatectomy. Death equivalent was defined as unresponsive grade 4 hepatic encephalopathy or ICP greater than 20 mmHg with clinical evidence of brain herniation. All animals in both (SMT and 0 g) control groups met the death equivalent before 51 hours following hepatectomy. Five of 6 animals in the 200-g group survived to 90 hours (P < 0.01). The mean ammonia, ICP, and international normalized ratio values were significantly lower in the 200-g group. CT volumetrics demonstrated increased volume regeneration at 48 hours following hepatectomy in the 200-g group compared with the SMT (P < 0.01) and 0-g (P < 0.01) groups. Ki-67 staining showed increased positive staining at 48 hours following hepatectomy (P < 0.01). Conclusion: The SRBAL improved survival, reduced ammonia, and accelerated liver regeneration in posthepatectomy ALF. Improved survival was associated with a neuroprotective benefit of SRBAL therapy. These favorable results warrant further clinical testing of the SRBAL.
引用
收藏
页码:329 / 342
页数:14
相关论文
共 50 条
  • [41] A clinical-scale BioArtificial Liver, developed for GMP, improved clinical parameters of liver function in porcine liver failure
    Clare Selden
    James Bundy
    Eloy Erro
    Eva Puschmann
    Malcolm Miller
    Delawir Kahn
    Humphrey Hodgson
    Barry Fuller
    Jordi Gonzalez-Molina
    Aurelie Le Lay
    Stephanie Gibbons
    Sherri Chalmers
    Sunil Modi
    Amy Thomas
    Peter Kilbride
    Agnes Isaacs
    Richard Ginsburg
    Helen Ilsley
    David Thomson
    Galya Chinnery
    Ncedile Mankahla
    Lizel Loo
    C. Wendy Spearman
    Scientific Reports, 7
  • [42] A bioartificial transgenic porcine whole liver expressing human proteins alleviates acute liver failure in pigs
    Xue, Wei-Song
    Zhang, Hao-Jie
    Ke, Jing-Jing
    Fu, Yu
    Peng, Qing
    Li, Li
    Gao, Yi
    Zhong, Ke-Bo
    HEPATOBILIARY & PANCREATIC DISEASES INTERNATIONAL, 2023, 22 (03) : 270 - 281
  • [43] A bioartificial transgenic porcine whole liver expressing human proteins alleviates acute liver failure in pigs
    Wei-Song Xue
    Hao-Jie Zhang
    Jing-Jing Ke
    Yu Fu
    Qing Peng
    Li Li
    Yi Gao
    Ke-Bo Zhong
    Hepatobiliary & Pancreatic Diseases International, 2023, 22 (03) : 270 - 281
  • [44] Liver transplantation as a lifesaving procedure for posthepatectomy liver failure and iatrogenic liver injuries
    Trygve Thorsen
    Jon Magnus Solheim
    Knut Jørgen Labori
    Pål-Dag Line
    Einar Martin Aandahl
    Langenbeck's Archives of Surgery, 2019, 404 : 301 - 308
  • [45] Support of acute liver failure patients with a bioartificial liver
    Watanabe, FD
    Demetriou, AA
    JOURNAL OF CLINICAL APHERESIS, 1996, 11 (03) : 138 - 142
  • [46] Assessment of bioartificial liver support in acute liver failure
    Hughes, RD
    Williams, R
    INTERNATIONAL JOURNAL OF ARTIFICIAL ORGANS, 1996, 19 (01): : 3 - 6
  • [47] BIOARTIFICIAL LIVER IN THE TREATMENT OF EXPERIMENTAL LIVER-FAILURE
    WILLIAMS, RF
    ROZGA, J
    ARNAOUT, W
    MOSCIONI, AD
    WINGARD, R
    HAKIM, RM
    DEMETRIOU, AA
    HEPATOLOGY, 1990, 12 (04) : 838 - 838
  • [48] Methodologic Issues in Prediction of Posthepatectomy Liver Failure
    Abbasi, Masoumeh
    Naderi, Mehdi
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 212 (04) : W109 - W109
  • [49] Is Grade A Posthepatectomy Liver Failure Clinically Relevant?
    Ko, B.
    Brajcich, B. C.
    Merkow, R. P.
    Pitt, H.
    Bilimoria, K. Y.
    Bentrem, D.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (SUPPL 1) : S91 - S92
  • [50] A Phase II/III clinical trial interim analysis of PERV transmissibility to acute liver failure patients treated with a porcine based bioartificial liver
    Pitkin, Z
    Switzer, WM
    Shanmugam, V
    Stevens, AC
    Solomon, BA
    Chapman, L
    Bhullar, V
    Hussain, A
    Matthews, A
    Sandstrom, P
    Mullon, CJP
    Heneine, W
    XENOTRANSPLANTATION, 2001, 8 : 34 - 34